CellAct Pharma presents further data supporting CAP7.1 for biliary tract cancers

3 June 2016

German cancer specialist CellAct Pharma has presented positive new data on CAP7.1 for the treatment of biliary tract cancers at the Annual Meeting of the American Society for Clinical Oncology (ASCO).

CAP7.1 is an adapted version of the well-established anti-cancer agent etoposide, converted by carboxylesterases into etoposide in selected tissues.

Analysis of population pharmacokinetic (PK) trial data indicated that higher blood concentrations of etoposide resulted in the majority of patients maintaining an increase in tumor size of below 20%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK